Health Care Adjustment Topic Analysis (I): Negative List of Drugs!

REVIEW: in the end what kind of varieties be included in the negative list?April 29, the National Medical Insurance Bureau on the "basic medical insurance drugs Interim Measures (draft)" for public comment"Draft" main content "Drug List" to develop and adjust the rules, the Medicare drug payment and ManagementWhere the former is the focus of attention of the industrya "draft" will bring up directly into the directory and call up the two levelsDirectly call up the list of drugs, there is one of the six cases, after expert review, directly bring up the "Drug List":drug regulatory authorities revoked, the revocation or cancellation of the drug approval documents of medicines; < br /> by authorities to ban the production, sale and use of drugs;by authorities, institutions included in the negative list of pharmaceuticals;considering clinical value, adverse reactions, drug economy and other factors, the assessment that the risks outweigh the benefits of medicines;into the "Drug List" of drugs by fraud or other illegal means; other circumstances should be directly transferred out ofstate regulationsToday, I try to analyze, in the end what kind of varieties be included in the negative listIf exhaustive, Wan Wang guidanceFirst, what is the negative list?negative list system is a model for government management of market access, government regulations achieved when the market players to enter the market through market access management, on the theory that in order to avoid or reduce the "market failure" exists It may lead to the risk and to intervene, but such interventions should reduce the probability of "government failure"The concept of a negative list, ideas and scope was extended and expanded, the new "Drug Administration Law" since December 1, 2019 implementation, some provinces and municipalities Drug administration for the first time will be applied to the negative list of drugs production quality security, safeguard the safe use of drugsSecond, the current negative list which Medicine Production and Circulation there? 1, national and provincial key monitoring (rational drug use) directory 2019 Nian 7 1st, the National Health Committee of Medical Administration Health Authority issued a "rational drug use on the issuance of the first countries to focus on monitoring drug List (of drugs and biological products) notice " Including gangliosides and other 20 kinds of drugs use will be the focus of monitoring, and "catalog" will be dynamically adjusted In addition, provincial and local, in recent years, have been released the relevant local version of key monitoring directory, as follows 2, drug prices and marketing dishonesty disciplinary rating on National Insurance Bureau "on the establishment of drug prices and strokes in the credit evaluation system guidance (draft)" (hereinafter referred to as "Opinion") comments "Opinions" require pharmaceutical companies to establish prices and marketing practices trustworthy commitment system; pharmaceutical companies price and marketing initiative to declare acts of dishonesty; pharmaceutical companies to price and marketing information check dishonesty; pharmaceutical companies price and marketing dishonesty credit rating; pharmaceutical companies and prices marketing dishonesty disciplinary classification; and pharmaceutical companies price and marketing dishonesty credit repair and other six systems Among them, dishonest pharmaceutical companies were divided into four other times integrated information display, once pharmaceutical companies have falsified the tender price, price fixing, low-cost disrupt the market, commercial bribery and other acts, will be subject to different degrees of punishment The establishment of these standards, means that pharmaceutical companies were hiring mining and marketing process, need to be more strictly examine and regulate their own behavior, or the inclusion of dishonesty, will likely lose strokes in qualifying 3, marketing authorization holders (drug manufacturers) quality and safety of pharmaceutical production negative list May 6, Anhui Province Food and Drug Administration public consultation "in Anhui Province marketing authorization holders (drugs manufacturer) quality and safety of pharmaceutical production negative list (draft) "comments a total of thirty Anhui has always been a benchmark medical reform, the introduction of relevant policies often draw on the industry, the introduction of Anhui relevant documents, from the perspective of market access, particularly worthy of attention and attention 4, the circulation of the two-vote system of negative list of 2017 8 Yue 1 Ri Chongqing Municipal Food and Drug Administration issued the "Chongqing pharmaceutical production and circulation enterprises 8th 2017 for consideration by the director's office the implementation of the "two-vote system" negative list ", a list of negative lists six behaviors in the production and distribution of drugs are included in the" negative list of two-vote system " The six acts include: 5, clinical application management antimicrobial agents to regulate medical practice, improve the therapeutic effect and reduce adverse reactions, so that patients receive safer and more effective treatment, 2014, Anhui Province according to the "national health and Family Planning Commission in 2014 on good clinical use of antibiotics management notice" (State health Office medical letter [2014] No 300) concerning requirements to strengthen issued a notice under the relevant medical institutions in Anhui Province intravenous infusion administration Since then, the country issued a notification on the clinical use of antibiotics under management Editor: Listen White Disclaimer: This article represents the views only of the author and do not represent the position of drug intellectual network, please share in the comments section to add; For reprint, please be sure to indicate the source and author of the article Related Tags: National , health insurance , the negative list 0 0